甲基泼尼松龙醋酸酯结构式
|
常用名 | 甲基泼尼松龙醋酸酯 | 英文名 | methylprednisolone acetate |
---|---|---|---|---|
CAS号 | 53-36-1 | 分子量 | 416.507 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 582.5±50.0 °C at 760 mmHg | |
分子式 | C24H32O6 | 熔点 | 206ºC | |
MSDS | 中文版 美版 | 闪点 | 196.5±23.6 °C | |
符号 |
GHS08 |
信号词 | Warning |
甲基泼尼松龙醋酸酯用途醋酸甲基强的松龙是一种强的松酮衍生物,是一种皮质类固醇激素。醋酸甲基强的松龙可减轻关节炎和其他关节疾病在体内引起的疼痛和肿胀[1][2]。 |
中文名 | 醋酸甲泼尼龙 |
---|---|
英文名 | methylprednisolone acetate |
中文别名 | 6A-甲基泼尼松龙醋酸酯 | 甲基强的龙醋酸盐 | 6Alpha-甲基波尼松龙21-醋酸 | 甲基泼尼松龙醋酸酯 |
英文别名 | 更多 |
描述 | 醋酸甲基强的松龙是一种强的松酮衍生物,是一种皮质类固醇激素。醋酸甲基强的松龙可减轻关节炎和其他关节疾病在体内引起的疼痛和肿胀[1][2]。 |
---|---|
相关类别 | |
体内研究 | 醋酸甲基强的松龙(30mg/kg,肌肉注射;连续10天额外口服剂量为13mg/kg)与LPS联合诱导股骨头早期AVN的典型特征[2]。动物模型:甲基强的松龙和脂糖诱导的小鼠股骨头坏死模型[2]剂量:30mg/kg;13mg/kg,连续10天给药:30mg/kg,肌肉注射;连续10天口服13mg/kg的额外剂量会导致7周后软骨细胞变性和纤维软骨表达。增加股骨头中CD31和VEGF-R2标记物的密度。 |
参考文献 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 582.5±50.0 °C at 760 mmHg |
熔点 | 206ºC |
分子式 | C24H32O6 |
分子量 | 416.507 |
闪点 | 196.5±23.6 °C |
精确质量 | 416.219879 |
PSA | 100.90000 |
LogP | 3.08 |
外观性状 | 灰白色固体 |
蒸汽压 | 0.0±3.7 mmHg at 25°C |
折射率 | 1.580 |
储存条件 | Refrigerator |
分子结构 | 1、 摩尔折射率:109.67 2、 摩尔体积(cm3/mol):329.3 3、 等张比容(90.2K):893.5 4、 表面张力(dyne/cm):54.1 5、 极化率(10-24cm3):43.47 |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:2 3.氢键受体数量:6 4.可旋转化学键数量:4 5.互变异构体数量:6 6.拓扑分子极性表面积101 7.重原子数量:30 8.表面电荷:0 9.复杂度:858 10.同位素原子数量:0 11.确定原子立构中心数量:8 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
Achyranthes bidentata extract exerts osteoprotective effects on steroid-induced osteonecrosis of the femoral head in rats by regulating RANKL/RANK/OPG signaling.
J. Transl. Med. 12 , 334, (2014) Steroid-induced osteonecrosis of the femoral head (steroid-induced ONFH) presents great challenges due to the various effects of steroids on multi-system pathways involved into osteoblast differentiat... |
|
Cholesterol- and lanolin-rich diets may protect against steroid-induced osteonecrosis in rabbits.
Acta Orthop. 84(6) , 593-7, (2013) It remains controversial how hypercholesterolemia influences the development of steroid-induced osteonecrosis (ON). We investigated the role of hypercholesterolemia induced by a cholesterol-rich diet ... |
|
Notes from the field: Department of Defense response to a multistate outbreak of fungal meningitis--United States, October 2012.
MMWR Morb. Mortal. Wkly. Rep. 62(38) , 800-1, (2013) On October 1, 2012, the Department of Defense (DoD) learned of a multistate outbreak of fungal meningitis in persons who received injections of methylprednisolone acetate (MPA) from a single compoundi... |
2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-6,10,13-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethylacetat |
6-METHYLPREDNISOLONE ACETATE |
(6α,11β)-11,17-Dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate |
Methylprednisolone acetate |
21-Acetoxy-11b,17-dihydroxy-6a-methylpregna-1,4-diene-3,20-dione |
(6a,11b)-21-(Acetyloxy)-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione |
6a-Methylprednisolone 21-Acetate |
CH3CO2CH(CH3)CH2OCH3 |
Depo-methylprednisolone |
MFCD00144786 |
EINECS 200-171-3 |
Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-, (6α,11β)- |
2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl acetate |
acétate de 2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-triméthyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodécahydro-3H-cyclopenta[a]phénanthrén-17-yl]-2-oxoéthyle |
6α-Methyl Prednisolone 21-Acetate |
6α-Methylprednisolone 21-acetate |
Solsolona |
Pregna-1,4-diene-3,20-dione, 11β,17,21-trihydroxy-6α-methyl-, 21-acetate (8CI) |